278 related articles for article (PubMed ID: 36727071)
1. The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer.
Davies CR; Guo T; Burke E; Stankiewicz E; Xu L; Mao X; Scandura G; Rajan P; Tipples K; Alifrangis C; Wimalasingham AG; Galazi M; Crusz S; Powles T; Grey A; Oliver T; Kudahetti S; Shaw G; Berney D; Shamash J; Lu YJ
Front Oncol; 2022; 12():1060864. PubMed ID: 36727071
[TBL] [Abstract][Full Text] [Related]
2. Circulating tumor cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.
De Laere B; Oeyen S; Van Oyen P; Ghysel C; Ampe J; Ost P; Demey W; Hoekx L; Schrijvers D; Brouwers B; Lybaert W; Everaert E; Van Kerckhove P; De Maeseneer D; Strijbos M; Bols A; Fransis K; Beije N; de Kruijff I; van Dam V; Brouwer A; van Dam PJ; Van den Eynden G; Rutten A; Sleijfer S; Vandebroek J; Van Laere S; Dirix L
Prostate; 2018 May; 78(6):435-445. PubMed ID: 29431193
[TBL] [Abstract][Full Text] [Related]
3. Circulating tumor cells as a biomarker predictive of sensitivity to docetaxel chemotherapy in patients with castration-resistant prostate cancer.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Anticancer Res; 2014 Nov; 34(11):6705-10. PubMed ID: 25368278
[TBL] [Abstract][Full Text] [Related]
4. Whole blood
Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA
Transl Androl Urol; 2021 Apr; 10(4):1688-1699. PubMed ID: 33968657
[TBL] [Abstract][Full Text] [Related]
5. Improving circulating tumor cells enumeration and characterization to predict outcome in first line chemotherapy mCRPC patients.
León-Mateos L; Casas H; Abalo A; Vieito M; Abreu M; Anido U; Gómez-Tato A; López R; Abal M; Muinelo-Romay L
Oncotarget; 2017 Aug; 8(33):54708-54721. PubMed ID: 28903376
[TBL] [Abstract][Full Text] [Related]
6. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Role of Circulating Tumor Cells in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Cabazitaxel: A Prospective Biomarker Study.
Koinis F; Zafeiriou Z; Messaritakis I; Katsaounis P; Koumarianou A; Kontopodis E; Chantzara E; Aidarinis C; Lazarou A; Christodoulopoulos G; Emmanouilides C; Hatzidaki D; Kallergi G; Georgoulias V; Kotsakis A
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760481
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer.
Goldkorn A; Ely B; Quinn DI; Tangen CM; Fink LM; Xu T; Twardowski P; Van Veldhuizen PJ; Agarwal N; Carducci MA; Monk JP; Datar RH; Garzotto M; Mack PC; Lara P; Higano CS; Hussain M; Thompson IM; Cote RJ; Vogelzang NJ
J Clin Oncol; 2014 Apr; 32(11):1136-42. PubMed ID: 24616308
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone with or without Lenalidomide in Metastatic Castration-resistant Prostate Cancer.
Vogelzang NJ; Fizazi K; Burke JM; De Wit R; Bellmunt J; Hutson TE; Crane E; Berry WR; Doner K; Hainsworth JD; Wiechno PJ; Liu K; Waldman MF; Gandhi A; Barton D; Jungnelius U; Fandi A; Sternberg CN; Petrylak DP
Eur Urol; 2017 Feb; 71(2):168-171. PubMed ID: 27522164
[TBL] [Abstract][Full Text] [Related]
10. Clinical Significance of Mesenchymal Circulating Tumor Cells in Patients With Oligometastatic Hormone-Sensitive Prostate Cancer Who Underwent Cytoreductive Radical Prostatectomy.
Yang G; Xie J; Zhang S; Gu W; Yuan J; Wang R; Guo C; Ye L; Peng B; Yao X; Yang B
Front Oncol; 2021; 11():812549. PubMed ID: 35127528
[TBL] [Abstract][Full Text] [Related]
11. Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy.
Okegawa T; Itaya N; Hara H; Tambo M; Nutahara K
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916908
[TBL] [Abstract][Full Text] [Related]
12. The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
Wang Z; Liu H; Zhao J; Chen J; Zhu S; Dai J; Ni Y; Xu N; Zhao F; He B; Zhang X; Liang J; Sun G; Liu Z; Shen P; Zeng H
Ann Transl Med; 2023 Mar; 11(5):201. PubMed ID: 37007568
[TBL] [Abstract][Full Text] [Related]
13. AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.
Seitz AK; Thoene S; Bietenbeck A; Nawroth R; Tauber R; Thalgott M; Schmid S; Secci R; Retz M; Gschwend JE; Ruland J; Winter C; Heck MM
Eur Urol; 2017 Nov; 72(5):828-834. PubMed ID: 28818355
[TBL] [Abstract][Full Text] [Related]
14. Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate Cancer.
Sharp A; Welti JC; Lambros MBK; Dolling D; Rodrigues DN; Pope L; Aversa C; Figueiredo I; Fraser J; Ahmad Z; Lu C; Rescigno P; Kolinsky M; Bertan C; Seed G; Riisnaes R; Miranda S; Crespo M; Pereira R; Ferreira A; Fowler G; Ebbs B; Flohr P; Neeb A; Bianchini D; Petremolo A; Sumanasuriya S; Paschalis A; Mateo J; Tunariu N; Yuan W; Carreira S; Plymate SR; Luo J; de Bono JS
Eur Urol; 2019 Nov; 76(5):676-685. PubMed ID: 31036442
[TBL] [Abstract][Full Text] [Related]
15. Associations between AR-V7 status in circulating tumour cells, circulating tumour cell count and survival in men with metastatic castration-resistant prostate cancer.
Belderbos BPS; Sieuwerts AM; Hoop EO; Mostert B; Kraan J; Hamberg P; Van MN; Beaufort CM; Onstenk W; van Soest RJ; Martens J; Sleijfer S; de Wit R; Mathijssen RHJ; Lolkema MP
Eur J Cancer; 2019 Nov; 121():48-54. PubMed ID: 31542641
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-Mesenchymal-Transition-Like Circulating Tumor Cell-Associated White Blood Cell Clusters as a Prognostic Biomarker in HR-Positive/HER2-Negative Metastatic Breast Cancer.
Guan X; Li C; Li Y; Wang J; Yi Z; Liu B; Chen H; Xu J; Qian H; Xu B; Ma F
Front Oncol; 2021; 11():602222. PubMed ID: 34150608
[TBL] [Abstract][Full Text] [Related]
17. Categorical versus continuous circulating tumor cell enumeration as early surrogate marker for therapy response and prognosis during docetaxel therapy in metastatic prostate cancer patients.
Thalgott M; Rack B; Eiber M; Souvatzoglou M; Heck MM; Kronester C; Andergassen U; Kehl V; Krause BJ; Gschwend JE; Retz M; Nawroth R
BMC Cancer; 2015 Jun; 15():458. PubMed ID: 26051431
[TBL] [Abstract][Full Text] [Related]
18. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.
Lindsay CR; Le Moulec S; Billiot F; Loriot Y; Ngo-Camus M; Vielh P; Fizazi K; Massard C; Farace F
BMC Cancer; 2016 Feb; 16():168. PubMed ID: 26923772
[TBL] [Abstract][Full Text] [Related]
19. Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.
Lozano R; Lorente D; Aragon IM; Romero-Laorden N; Nombela P; Mateo J; Reid AHM; Cendón Y; Bianchini D; Llacer C; Sandhu SK; Sharp A; Rescigno P; Garcés T; Pacheco MI; Flohr P; Massard C; López-Casas PP; Castro E; de Bono JS; Olmos D
Cancers (Basel); 2021 May; 13(10):. PubMed ID: 34066080
[TBL] [Abstract][Full Text] [Related]
20. Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts.
Lorente D; Olmos D; Mateo J; Dolling D; Bianchini D; Seed G; Flohr P; Crespo M; Figueiredo I; Miranda S; Scher HI; Terstappen LWMM; de Bono JS
Ann Oncol; 2018 Jul; 29(7):1554-1560. PubMed ID: 29741566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]